课题基金 / 基金详情

Mild intermittent hypoxia: A therapeutic modality to mitigate co-morbidities and promote recovery of respiratory motor function in spinal cord injured patients with sleep apnea

Mild intermittent hypoxia: A therapeutic modality to mitigate co-morbidities and promote recovery of respiratory motor function in spinal cord injured patients with sleep apnea
轻度间歇性缺氧:一种减轻睡眠呼吸暂停脊髓损伤患者的合并症并促进呼吸运动功能恢复的治疗方式
批准号:
10162332
负责人:
Gino S Panza
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-11-01 至 2022-04-30

项目摘要

项目成果

Gino S Panza的其他基金

相似基金

相关文献

中文摘要
翻译
阻塞性睡眠呼吸暂停(OSA)的患病率在脊髓完整的退伍军人中很高, 四肢瘫痪患者的患病率更高(即74%)。不完全脊髓损伤(SCI)伴 并发OSA伴有自主神经、心血管和神经认知共病,以及, 呼吸和肢体运动功能障碍。缓解这些并发症的治疗选择,同时促进 呼吸运动功能的恢复范围从有限到不存在96。当前的总目标 建议是调查每天暴露在轻度间歇性低氧(MIH)[是否会增加上呼吸道 肌肉活动导致夜间在家持续正压[(CPAP)]使用量增加 (小时/夜间)。MIH与改进的夜间居家CPAP相结合的直接效果可以作为 缓解自主神经、心血管和神经认知共病的多管齐下的治疗方法 同时促进脊髓损伤合并阻塞性睡眠呼吸暂停患者呼吸运动功能的恢复。 我们认为,每天接触MIH可以降低治疗睡眠呼吸暂停所需的积极压力。 家庭,因此可以提高家庭治疗的依从性。提高遵从性可有助于 减轻上面列出的并存疾病。此外,MIH也可能直接影响这些共病,而 促进呼吸神经肌肉功能的恢复。为了实现我们的目标,我们将招募个人 SCI和并发OSA,并随机分配到两组中的一组。[参与者将是 组分配盲目]。其中一组每天接受MIH治疗,为期15天,为期3周。 期间(即5天/周),另一组暴露在环境空气中(即对照组)。此外, 两组都将在整个方案期间接受[夜间在家]CPAP治疗。一开始, 在协议的中段和末尾,将获得一些措施来评估暴露于MIH是否可以 有效缓解上述并存,[并减少治疗所需压力 请客]OSA。血压是主要的结果,将在24小时内使用 方案前后动态血压自动监测仪。此外,自动和手动 血压测量将在MIH治疗前、治疗中和治疗后进行。神经认知功能 协议的开始和结束将使用侧重于警觉性、记忆力和 执行职能。自主神经功能将在治疗期间的日常基础上通过心率和 BP变异性分析。治疗性CPAP压力、主动和被动临界闭合压力 在方案的开始、中期和结束时将测量上呼吸道。[此外,二氧化碳 通过监测潮气末二氧化碳浓度,每天在每次就诊的前10分钟内测量保留量。]至 监测MIH作为治疗脊髓损伤和阻塞性睡眠呼吸暂停综合征的安全性和有效性,许多生物标志物将 根据15天方案开始、中期和结束时采集的血液样本进行测量。鲜血 测试将确定潜在的代谢(即脂谱、血红蛋白A1C)、炎症性(即高敏感性C- 反应蛋白、肿瘤坏死因子-α、白介素1、6、8和CCL3-887)和血管生成/血管生成(可诱导缺氧 因子1α和血管内皮生长因子)。最后,将测量红细胞计数(红细胞压积)以 监测红细胞增多症。传播由此报告的结果以及未来的项目,可能会导致 为那些脊髓损伤[和因以下原因造成的医学后遗症]的患者提供更先进和及时的治疗 阻塞性睡眠呼吸暂停症]在退伍军人中。因此,这个项目将决定MIH是否与 CPAP可以作为一种治疗方法,在促进康复的同时减轻许多并存的疾病 退伍军人脊髓损伤合并阻塞性睡眠呼吸暂停综合征患者的神经肌肉功能。
英文摘要
The prevalence of obstructive sleep apnea (OSA) is high in Veterans with an intact spinal cord99 and the prevalence is even greater (i.e.74%) in patients with tetraplegia19. Incomplete spinal cord injury (SCI) with concurrent OSA is accompanied by autonomic, cardiovascular and neurocognitive co-morbidities, as well as, respiratory and limb motor dysfunction. Treatment options to mitigate these co-morbidities while promoting recovery of respiratory motor function range from limited to non-existent96. The overall goal of the present proposal is to investigate if daily exposure to mild intermittent hypoxia (MIH) [can increase upper airway muscle activity leading to increased nightly in-home] continuous positive airway pressure [(CPAP) usage (Hours/night). The direct effects of MIH in combination with the improved nightly in-home CPAP] can serve as a multipronged therapeutic approach to mitigate autonomic, cardiovascular and neurocognitive co-morbidities while promoting recovery of respiratory motor function in individuals suffering from SCI and concurrent OSA. We believe that exposure to daily MIH could reduce the positive pressure required to treat sleep apnea at home and as a result could improve in-home treatment adherence. Improved adherence could contribute to mitigating the co-morbidities listed above. In addition, MIH might also directly impact these co-morbidities while promoting recovery of respiratory neuromuscular function. To accomplish our goal we will recruit individuals with SCI and concurrent OSA, and randomly assign them to one of two groups. [The participants will be blinded to group assignment]. One group will be treated daily with MIH for a period of 15 days over a 3 week period (i.e. 5 days/week) and the other group will be exposed to ambient air (i.e. control group). In addition, both groups will be treated with [nightly in-home] CPAP over the length of the protocol. At the beginning, middle and end of the protocol a number of measures will be obtained to assess if exposure to MIH can effectively mitigate the co-morbidities listed above, [as well as reduce the therapeutic pressure required to treat] OSA. Blood pressure is a primary outcome and will be measured over a 24 hour period with an ambulatory automated BP monitoring device before and after the protocol. Additionally, automated and manual measures of BP will be obtained before, during, and after MIH treatment sessions. Neurocognitive function at the beginning and end of the protocol will be assessed using tests that focus on vigilance, memory and executive function. Autonomic function will be assessed on a day to day basis during therapy via heart rate and BP variability analysis. The therapeutic CPAP pressure, and active and passive critical closing pressure of the upper airway will be measured at the beginning, middle and end of the protocol. [Additionally, carbon dioxide retention will be measured daily during the first 10 minutes of each visit by monitoring end tidal CO2.]To monitor the safety and efficacy of MIH as a treatment for SCI and OSA, numerous biomarkers will be measured from blood samples collected at the beginning, middle and end of the 15 day protocol. The blood tests will identify potential metabolic (i.e. lipid profile, hemoglobin A1C), inflammatory (i.e. high sensitivity C‐ reactive protein, TNF-alpha, Interleukin 1, 6, 8 and CCL3-887) and angiogenic/vasculogenic (hypoxia inducible factor 1α and vascular endothelial growth factor). Lastly, red blood cell count (hematocrit) will be measured to monitor for polycythemia. The dissemination of the outcomes reported from this, and future projects, could lead to more advanced and timely treatments for those with spinal cord injuries [and medical sequela due to obstructive sleep apnea] in the Veteran population. Therefore, this project will determine if MIH combined with CPAP can be used as a treatment to mitigate numerous co-morbidities while promoting recovery neuromuscular function in Veterans with SCI and concurrent OSA.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mild Intermittent Hypoxia: A Prophylactic for Autonomic Dysfunction in Individuals with Spinal Cord Injuries
Mild Intermittent Hypoxia: A Prophylactic for Autonomic Dysfunction in Individuals with Spinal Cord Injuries
国内基金
海外基金
湍流和化学交互作用对H2-Air-H2O微混燃烧中NO生成的影响研究
  • 批准号:
    51976048
  • 项目类别:
    面上项目
  • 资助金额:
    61.0万元
  • 批准年份:
    2019
  • 负责人:
    邱朋华
  • 依托单位: